| Alpha Medical Clinic | |
|
401 S Main St Suite A-4 Alpharetta GA 30009-1974 | |
| (770) 772-4044 | |
| (770) 772-4227 |
| Full Name | Alpha Medical Clinic |
|---|---|
| Speciality | Internal Medicine |
| Location | 401 S Main St, Alpharetta, Georgia |
| Authorized Official Name and Position | Dhiraj A Patel (OWNER) |
| Authorized Official Contact | 7707724044 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Alpha Medical Clinic 401 S Main St Suite A-4 Alpharetta GA 30009-1974 Ph: (770) 772-4044 | Alpha Medical Clinic 401 S Main St Suite A-4 Alpharetta GA 30009-1974 Ph: (770) 772-4044 |
| NPI Number | 1659556157 |
|---|---|
| Provider Enumeration Date | 01/02/2008 |
| Last Update Date | 08/31/2010 |
| Medicare PECOS PAC ID | 3274528914 |
|---|---|
| Medicare Enrollment ID | O20040420000815 |
News Archive
Health experts and anti-obesity groups have called for a total ban on junk-food advertising during peak children's viewing times. This comes in the wake of the release of the research finding of the Obesity Policy Coalition that conducted a telephone survey of 1,521 adults says that 84 per cent of consumers believe children should be protected from unhealthy food advertising.
The anti-inflammatory class of drugs NSAIDs have shown great promise in preventing cancers including colon, esophagus and skin. However, they can increase the risks of heart attacks, ulcers and rare but potentially life-threatening bleeds.
Cubist Pharmaceuticals, Inc., a leading acute care therapeutics company, today announced that the recently-completed Phase 2 study of CXA-101, a novel cephalosporin, compared to ceftazidime for the treatment of complicated urinary tract infections (cUTI) in adults met its study objectives.
Schering-Plough Corporation, (NYSE: SGP), today announced that the European Medicines Agency (EMEA) has validated (accepted for review) the company's Marketing Authorization Application (MAA) for a fixed-dose combination of mometasone furoate and formoterol fumarate for the maintenance treatment of asthma in patients 12 years of age and older.
› Verified 6 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1659556157 | NPI | - | NPPES |
| GRP4579 | Other | MEDICARE GROUP NO |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207R00000X | Internal Medicine | (* (Not Available)) | Primary |
| Provider Name | Dhiraj A Patel |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1891863148 PECOS PAC ID: 1456437706 Enrollment ID: I20120118000345 |
News Archive
Health experts and anti-obesity groups have called for a total ban on junk-food advertising during peak children's viewing times. This comes in the wake of the release of the research finding of the Obesity Policy Coalition that conducted a telephone survey of 1,521 adults says that 84 per cent of consumers believe children should be protected from unhealthy food advertising.
The anti-inflammatory class of drugs NSAIDs have shown great promise in preventing cancers including colon, esophagus and skin. However, they can increase the risks of heart attacks, ulcers and rare but potentially life-threatening bleeds.
Cubist Pharmaceuticals, Inc., a leading acute care therapeutics company, today announced that the recently-completed Phase 2 study of CXA-101, a novel cephalosporin, compared to ceftazidime for the treatment of complicated urinary tract infections (cUTI) in adults met its study objectives.
Schering-Plough Corporation, (NYSE: SGP), today announced that the European Medicines Agency (EMEA) has validated (accepted for review) the company's Marketing Authorization Application (MAA) for a fixed-dose combination of mometasone furoate and formoterol fumarate for the maintenance treatment of asthma in patients 12 years of age and older.
› Verified 6 days ago
| Provider Name | Neil Patel |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1225448178 PECOS PAC ID: 8628334562 Enrollment ID: I20171109002904 |
News Archive
Health experts and anti-obesity groups have called for a total ban on junk-food advertising during peak children's viewing times. This comes in the wake of the release of the research finding of the Obesity Policy Coalition that conducted a telephone survey of 1,521 adults says that 84 per cent of consumers believe children should be protected from unhealthy food advertising.
The anti-inflammatory class of drugs NSAIDs have shown great promise in preventing cancers including colon, esophagus and skin. However, they can increase the risks of heart attacks, ulcers and rare but potentially life-threatening bleeds.
Cubist Pharmaceuticals, Inc., a leading acute care therapeutics company, today announced that the recently-completed Phase 2 study of CXA-101, a novel cephalosporin, compared to ceftazidime for the treatment of complicated urinary tract infections (cUTI) in adults met its study objectives.
Schering-Plough Corporation, (NYSE: SGP), today announced that the European Medicines Agency (EMEA) has validated (accepted for review) the company's Marketing Authorization Application (MAA) for a fixed-dose combination of mometasone furoate and formoterol fumarate for the maintenance treatment of asthma in patients 12 years of age and older.
› Verified 6 days ago
News Archive
Health experts and anti-obesity groups have called for a total ban on junk-food advertising during peak children's viewing times. This comes in the wake of the release of the research finding of the Obesity Policy Coalition that conducted a telephone survey of 1,521 adults says that 84 per cent of consumers believe children should be protected from unhealthy food advertising.
The anti-inflammatory class of drugs NSAIDs have shown great promise in preventing cancers including colon, esophagus and skin. However, they can increase the risks of heart attacks, ulcers and rare but potentially life-threatening bleeds.
Cubist Pharmaceuticals, Inc., a leading acute care therapeutics company, today announced that the recently-completed Phase 2 study of CXA-101, a novel cephalosporin, compared to ceftazidime for the treatment of complicated urinary tract infections (cUTI) in adults met its study objectives.
Schering-Plough Corporation, (NYSE: SGP), today announced that the European Medicines Agency (EMEA) has validated (accepted for review) the company's Marketing Authorization Application (MAA) for a fixed-dose combination of mometasone furoate and formoterol fumarate for the maintenance treatment of asthma in patients 12 years of age and older.
› Verified 6 days ago
Living Well Primary Care, Llc Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 12460 Crabapple Rd Ste 202-313, Alpharetta, GA 30004 Phone: 404-819-7660 Fax: 404-393-7788 | |
James L. Stewart, Md Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 3005 Old Alabama Rd, Suite 230, Alpharetta, GA 30022 Phone: 770-740-8550 Fax: 770-740-9338 | |
New Era Healthcare Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 11175 Cicero Drive, Suite 100, Alpharetta, GA 30022 Phone: 678-534-5900 Fax: 678-534-5910 | |
Urgent Care Clinics Llc Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 1975 Nocturne Dr Unit 2203, Alpharetta, GA 30009 Phone: 216-731-1919 | |
Milton Medical Group, Llc Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 735 N Main St, 1100, Alpharetta, GA 30009 Phone: 678-827-9157 Fax: 470-299-6262 | |
Living Healthy Medical Llc Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 5755 North Point Parkway, Suite # 89, Alpharetta, GA 30022 Phone: 770-450-4225 | |
Mind And Body Wellness Center Inc. Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 3180 N Point Pkwy Ste 302, Alpharetta, GA 30005 Phone: 404-800-5181 Fax: 404-800-5797 |